Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

NCT06229340 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

RAS Mutation
Ras (Kras or Nras) Gene Mutation
Colorectal Cancer Recurrent
Pancreas Cancer
Lung Cancer
Melanoma
Refractory Cancer

Interventions

DRUG: Leflunomide
DRUG: The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab

Sponsor

N.N. Petrov National Medical Research Center of Oncology